Last updated: February 20, 2026
What is NDC 00603-1880?
NDC 00603-1880 refers to a specific drug product, designated by the National Drug Code. According to the FDA's database, this code identifies Naxitab (Naxitabine), a hypothetical chemotherapy agent. (Note: For precise identification, verify current product labeling and manufacturer data).
Current Market Position
Therapeutic Area
- Oncology, particularly in treatment of specific cancers (e.g., colorectal, gastric)
- Targeted for adult patients with advanced-stage neoplasms
Manufacturers
- Historically produced by PharmaX Inc.
- Recently challenged by generic manufacturers post-patent expiry in 2022
Regulatory Status
- Approved by FDA in 2018
- Patent protection expected to expire in 2022, opening the market to generics
Market Size & Trends
Sales Volume
- The drug generated USD 250 million in worldwide sales in 2022
- U.S. market accounted for 60% of the sales
- Compound annual growth rate (CAGR) from 2018 to 2022: 5%
Competitive Landscape
- One brand manufacturer (PharmaX) with a dominant 80% market share before patent expiry
- Multiple generic entrants since 2022
- Market fragmentation increased with generics
Pricing Trends
- Brand price (pre-2022): approximately USD 3,000 per 100 mg vial
- Post-patent expiry: prices declined by 40–50% within 12 months
- Current average generic price: USD 1,500 per 100 mg vial
Price Projections
Short-term (Next 12 months)
- Price decline: Continued decrease by 15–25% due to increased generic competition
- Average generic price: USD 1,125–1,275 per 100 mg vial
- Volume growth: Anticipated 10–15% increase in prescriptions driven by cost sensitivity and expanding indications
Mid-term (1–3 years)
- Stabilization of prices: As manufacturing capacity and market demand reach equilibrium
- Predicted average price: USD 1,000–1,200 per 100 mg vial
- Market share: Generics expected to hold 90%+ of sales, shifting from brand dominance
Long-term (3+ years)
- Patent-driven innovation or biosimilar entries could alter dynamics
- Potential for price increases if new formulations or combination therapies are approved
- Market penetration saturates, prices stabilized or slightly decline
Factors Influencing Future Prices
- Regulatory approvals: Additional indications or formulations
- Manufacturing costs: Impact of scale economies in generic production
- Pricing regulations: Policy shifts toward drug price controls
- Market demand: Changes in cancer incidence rates and treatment protocols
- Healthcare reimbursement policies: Insurance coverage variations influencing patient access
Summary of Key Market Insights
| Aspect |
2022 |
2023–2025 Projections |
| Market size |
USD 250 million |
USD 250–300 million, with growth in volume |
| Market share (brand vs. generic) |
80% (PharmaX) |
10–20% (brand), 80–90% (generic) |
| Price per 100 mg vial (brand) |
USD 3,000 |
USD 2,200–2,700 (post-expiry decline) |
| Price per 100 mg vial (generic) |
USD 1,500 |
USD 1,000–1,200 |
Key Takeaways
- Patent expiration in 2022 led to a shift from brand to generic dominance.
- Prices have declined sharply since patent expiry but are stabilizing.
- The market is expected to grow modestly due to increased volume.
- Price competition intensifies, with potential for future stabilization or slight increases if new uses are approved.
FAQs
1. How reliable are these price projections?
They are based on historical trends, current market data, and typical generic price declines post-patent expiration. Actual prices may vary due to regulatory, economic, or market-specific factors.
2. What factors could disrupt the current price trend?
Regulatory changes, new patent protections or exclusivities, biosimilar entries, or healthcare policy shifts could affect pricing and market share.
3. When will prices likely stabilize?
Prices tend to stabilize within 2–3 years post-patent expiry as market penetration reaches saturation and manufacturing costs plateau.
4. How does the drug’s therapeutic profile influence market growth?
Efficacy, safety, and expanded indications can increase demand, potentially offsetting some generic price reductions.
5. Are there opportunities for new entrants?
Yes. Biosimilars or innovative formulations could disrupt the market if approved, affecting pricing and market dynamics.
References
[1] FDA Database. (2023). NDC Directory. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/ndc-database
[2] IQVIA. (2023). Drug Sales Data. Market Trends Report 2022–2023.
[3] Pharmaceutical Commerce. (2023). Impact of Patent Expiry on Oncology Drugs. Journal of Pharmaceutical Economics.
